Endomag

Endomag is a commercial-stage diagnostics company that has developed Magtrace®, a magnetic nanoparticle tracer for sentinel lymph node biopsy in breast cancer. Its technology enables a 'Delayed SLNB' approach, potentially allowing up to 80% of high-risk DCIS patients to avoid unnecessary axillary surgery. The company's platform, which includes the Sentimag® detection probe, provides a clinically effective, radiation-free, and more convenient solution for cancer staging, with over 200,000 patients treated globally.

Magnetic sensing platform using superparamagnetic iron oxide nanoparticles (SPIONs) for lymphatic mapping and surgical guidance. Includes the Magtrace injectable tracer and the Sentimag handheld detection probe.

Competes primarily against the established standard of care: radioactive technetium-99m, often combined with blue dye. Alternative technologies include fluorescent dyes (e.g., indocyanine green with specialized cameras) and other magnetic systems. Endomag's first-mover advantage in magnetic SLNB and strong clinical data are key differentiators.